HC Wainwright Reiterates "Buy" Rating for Valneva (NASDAQ:VALN)

Key Points

• HC Wainwright has reaffirmed a "buy" rating for Valneva (NASDAQ:VALN) with a price target of $18.00, suggesting a potential upside of 90.50% from the stock's recent close.
• The stock has recently experienced a drop of 18.8%, trading at around $9.45, with an average target price of $16.00 from analysts.
• Valneva reported a quarterly EPS of ($0.16), beating estimates, and its revenue for the quarter was $54.84 million, exceeding the consensus estimate of $46.28 million.

Valneva (NASDAQ:VALN - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright's price objective indicates a potential upside of 90.50% from the stock's previous close.

Separately, Guggenheim reduced their target price on Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $16.00.

Valneva Stock Down 18.8%

Valneva stock traded down $2.1910 during midday trading on Monday, reaching $9.4490. The stock had a trading volume of 321,197 shares, compared to its average volume of 65,154. The company has a market capitalization of $804.02 million, a P/E ratio of -9.53 and a beta of 1.77. The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Valneva has a 12 month low of $3.62 and a 12 month high of $12.25. The company has a fifty day moving average price of $7.41 and a two-hundred day moving average price of $6.97.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%.The business had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. As a group, equities analysts expect that Valneva will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Marex Group plc acquired a new stake in shares of Valneva in the second quarter worth about $64,000. GAMMA Investing LLC bought a new position in Valneva during the first quarter worth about $94,000. Wells Fargo & Company MN lifted its holdings in shares of Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in Valneva during the second quarter valued at approximately $8,240,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.